BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Average Rating of “Moderate Buy” by Brokerages

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have earned an average rating of “Moderate Buy” from the seven research firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $15.57.

BCRX has been the topic of several recent research reports. Evercore ISI boosted their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. Royal Bank of Canada reiterated an “outperform” rating and set a $11.00 target price (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Wedbush began coverage on BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 target price on the stock. JMP Securities reiterated a “market outperform” rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of BCRX. Principal Financial Group Inc. lifted its stake in BioCryst Pharmaceuticals by 1,058.1% in the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock valued at $3,127,000 after buying an additional 375,890 shares in the last quarter. Aigen Investment Management LP lifted its stake in shares of BioCryst Pharmaceuticals by 75.0% during the 3rd quarter. Aigen Investment Management LP now owns 28,661 shares of the biotechnology company’s stock worth $218,000 after purchasing an additional 12,280 shares during the period. Counterweight Ventures LLC lifted its stake in shares of BioCryst Pharmaceuticals by 591.7% during the 3rd quarter. Counterweight Ventures LLC now owns 93,384 shares of the biotechnology company’s stock worth $710,000 after purchasing an additional 79,884 shares during the period. Intech Investment Management LLC purchased a new position in shares of BioCryst Pharmaceuticals during the 3rd quarter worth $412,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of BioCryst Pharmaceuticals by 5.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,887,994 shares of the biotechnology company’s stock worth $14,349,000 after purchasing an additional 102,860 shares during the period. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Down 1.3 %

Shares of BCRX stock opened at $7.64 on Friday. The stock has a market capitalization of $1.60 billion, a PE ratio of -12.52 and a beta of 1.85. BioCryst Pharmaceuticals has a 52-week low of $4.03 and a 52-week high of $9.50. The stock’s 50-day moving average price is $8.13 and its 200 day moving average price is $7.84.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The company had revenue of $131.50 million during the quarter, compared to analysts’ expectations of $126.64 million. The firm’s revenue for the quarter was up 40.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.28 EPS. Analysts expect that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.